203 related articles for article (PubMed ID: 35987691)
1. Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice.
Cuddy LK; Alia AO; Salvo MA; Chandra S; Grammatopoulos TN; Justman CJ; Lansbury PT; Mazzulli JR; Vassar R
Mol Neurodegener; 2022 Aug; 17(1):54. PubMed ID: 35987691
[TBL] [Abstract][Full Text] [Related]
2. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease.
Sadleir KR; Kandalepas PC; Buggia-Prévot V; Nicholson DA; Thinakaran G; Vassar R
Acta Neuropathol; 2016 Aug; 132(2):235-256. PubMed ID: 26993139
[TBL] [Abstract][Full Text] [Related]
3. Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease.
Andrew RJ; Fernandez CG; Stanley M; Jiang H; Nguyen P; Rice RC; Buggia-Prévot V; De Rossi P; Vetrivel KS; Lamb R; Argemi A; Allaert ES; Rathbun EM; Krause SV; Wagner SL; Parent AT; Holtzman DM; Thinakaran G
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9665-E9674. PubMed ID: 29078331
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
[TBL] [Abstract][Full Text] [Related]
5. Poloxamer-188 Exacerbates Brain Amyloidosis, Presynaptic Dystrophies, and Pathogenic Microglial Activation in 5XFAD Mice.
Di Meco A; Kemal S; Popovic J; Chandra S; Sadleir K; Vassar R
Curr Alzheimer Res; 2022; 19(4):317-329. PubMed ID: 35579170
[TBL] [Abstract][Full Text] [Related]
6. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development.
Zhang XM; Cai Y; Xiong K; Cai H; Luo XG; Feng JC; Clough RW; Struble RG; Patrylo PR; Yan XX
Eur J Neurosci; 2009 Dec; 30(12):2271-83. PubMed ID: 20092570
[TBL] [Abstract][Full Text] [Related]
7. Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.
Sadleir KR; Eimer WA; Kaufman RJ; Osten P; Vassar R
PLoS One; 2014; 9(7):e101643. PubMed ID: 24992504
[TBL] [Abstract][Full Text] [Related]
8. BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology.
Cai Y; Zhang XM; Macklin LN; Cai H; Luo XG; Oddo S; Laferla FM; Struble RG; Rose GM; Patrylo PR; Yan XX
Neurotox Res; 2012 Feb; 21(2):160-74. PubMed ID: 21725719
[TBL] [Abstract][Full Text] [Related]
9. Tau deletion reduces plaque-associated BACE1 accumulation and decelerates plaque formation in a mouse model of Alzheimer's disease.
Peters F; Salihoglu H; Pratsch K; Herzog E; Pigoni M; Sgobio C; Lichtenthaler SF; Neumann U; Herms J
EMBO J; 2019 Dec; 38(23):e102345. PubMed ID: 31701556
[TBL] [Abstract][Full Text] [Related]
10. Correction of microtubule defects within Aβ plaque-associated dystrophic axons results in lowered Aβ release and plaque deposition.
Yao Y; Nzou G; Alle T; Tsering W; Maimaiti S; Trojanowski JQ; Lee VM; Ballatore C; Brunden KR
Alzheimers Dement; 2020 Oct; 16(10):1345-1357. PubMed ID: 32918367
[TBL] [Abstract][Full Text] [Related]
11. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice.
Kim W; Ma L; Lomoio S; Willen R; Lombardo S; Dong J; Haydon PG; Tesco G
Mol Neurodegener; 2018 Feb; 13(1):6. PubMed ID: 29391027
[TBL] [Abstract][Full Text] [Related]
12. Impaired JIP3-dependent axonal lysosome transport promotes amyloid plaque pathology.
Gowrishankar S; Wu Y; Ferguson SM
J Cell Biol; 2017 Oct; 216(10):3291-3305. PubMed ID: 28784610
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer's disease.
Devi L; Alldred MJ; Ginsberg SD; Ohno M
PLoS One; 2012; 7(3):e32792. PubMed ID: 22403710
[TBL] [Abstract][Full Text] [Related]
14. Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice.
Devi L; Ohno M
Eur J Neurosci; 2010 Jan; 31(1):110-8. PubMed ID: 20092558
[TBL] [Abstract][Full Text] [Related]
15. Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level.
Sadleir KR; Eimer WA; Cole SL; Vassar R
Mol Neurodegener; 2015 Jan; 10():1. PubMed ID: 25567526
[TBL] [Abstract][Full Text] [Related]
16. A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice.
Devi L; Ohno M
Mol Brain; 2015 Mar; 8():19. PubMed ID: 25884928
[TBL] [Abstract][Full Text] [Related]
17. An age-related axon terminal pathology around the first olfactory relay that involves amyloidogenic protein overexpression without plaque formation.
Cai Y; Xue ZQ; Zhang XM; Li MB; Wang H; Luo XG; Cai H; Yan XX
Neuroscience; 2012 Jul; 215():160-73. PubMed ID: 22542680
[TBL] [Abstract][Full Text] [Related]
18. Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages.
Devi L; Ohno M
Neuroscience; 2015 Oct; 307():128-37. PubMed ID: 26314636
[TBL] [Abstract][Full Text] [Related]
19. The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques.
Kandalepas PC; Sadleir KR; Eimer WA; Zhao J; Nicholson DA; Vassar R
Acta Neuropathol; 2013 Sep; 126(3):329-52. PubMed ID: 23820808
[TBL] [Abstract][Full Text] [Related]
20. L-type calcium channel antagonist isradipine age-dependently decreases plaque associated dystrophic neurites in 5XFAD mouse model.
Wickline JL; Smith S; Shin R; Odfalk K; Sanchez J; Javors M; Ginsburg B; Hopp SC
Neuropharmacology; 2023 Apr; 227():109454. PubMed ID: 36740015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
